Kedrion Biopharma runner up at the Premio Equita for the bond issued in July 2017
The prize is awarded to the companies that made the best use of the capital markets
Hemophilia: Kedrion signs on to groundbreaking PARTNERS programme
Goal is to improve access to replacement therapies for coagulation disorders in Europe
Kedrion and Cerus enter distribution agreement for INTERCEPT in Italy
Agreement covers complete INTERCEPT product line: platelets, plasma and red blood cells
Kedrion supports Factor VIII and Factor IX donation in Afghanistan
The “Indira Gandhi Pediatric Hospital” in Kabul receives almost 2 million IU of Italian Plasma
Italy donates plasma-derived therapies to Armenia
Kedrion supports transfer of 790k IU of coagulation factors to Armenian Hematology Center
Kedrion supports Italian product donation to Serbia
Three million Factor VIII units donated to Belgrade’s Clinical Center patients
Kedrion Biopharma signs agreement with European Hemophilia Consortium (EHC)
The agreement aims to improve patient access to coagulation disorders treatments in Europe
New company AO Kirov Plasma established in Russia
It’s a joint venture between Kedrion Biopharma, Nacimbio and Pharmastandard
Kedrion Biopharma strengthens its presence in Russia
Memorandum of Understanding with Russian pharmaceutical companies for a joint plasma products manufacturing program
Kedrion Biopharma consolidates presence on Russian market
Joint venture with Nacimbio of RosTECH group for a technology transfer to Kirov plant
